Table 2.
Interim results of randomized trials incorporating oxaliplatin in preoperative chemoradiation regimens.
| Study | Treatment | N | RT dose (Gy) Total/per fraction |
pCR | SPS |
|---|---|---|---|---|---|
| STAR01 [56] | 5-FU CIV | 379 | 50.4/1.8 | 16% | 80% |
| 5-FU CIV + OX 60 mg/m2 | 368 | 50.4/1.8 | 16% | 82% | |
| ACCORD 12/0405-Prodige 2 [57] | CAP 800 mg/m2 | 299 | 45/1.8 | 13.9% | 75% |
| CAP 800 mg/m2 + OX 50 mg/m2 | 299 | 50/1.8 | 19.2% | 75% | |
| CAO/ARO/AIO-04 [55] | 5-FU; adj 5-FU | 637 | 50.4/1.8 | 13.1% | 88.1% |
| 5-FU + OX 50 mg/m2; adj FolFox6 | 628 | 50.4/1.8 | 17.6% | 87.8% | |
| NSABP R-04 [58] | 5-FU CIV ± OX 50 mg/m2 | 719 | 50.4/1.8 | 18.8% | 61.2% |
| CAP 825 mg/m2 ± OX 50 mg/m2 | 707 | 50.4/1.8 | 22.2% | 62.7% |
CAP: capecitabine; RT: radiotherapy; pCR: pathological complete response; SPS: sphincter preserving surgery.